This podcast episode explores the potential disruptive impact of GLP-1s, a new class of weight-loss medications, with Terzepatide being a key example. It delves into Eli Lilly's transformation, from the success of Prozac to their current breakthrough drug, Terzepatide, and their efforts to meet the massive demand for the drug. The episode also discusses the development of retitrutide, a potential breakthrough obesity drug, and the intense competition in the biotech industry. Furthermore, it highlights the potential uses of drugs like Ozempic in treating various health conditions and the ongoing clinical trials for using Ozempic in treating alcohol use disorder. The podcast also explores the potential impact of weight-loss drugs on industries such as bariatric surgery and food, as well as the personal experiences of individuals struggling with weight management. Finally, it concludes with the speaker's reflection on their own weight loss journey and their upcoming adventure of summiting Mount Whitney.
